“Response Evaluation Criteria in Solid Tumors” (known as RECIST) is a standard methodology of measuring a patient’s tumor response to treatment. However, it is not always the best method to measure treatment outcomes for desmoid patients.
To address the RECIST shortcomings, the DTRF, our medical advisors, and pharmaceutical medical professionals developed a radiomics working group in late 2021. This group is identifying better imaging methods for measuring treatment response.
We thank our working group chairs, Drs. Mrinal Gounder and Larry Schwartz, for leading this project which will impact the future of radiology in desmoid tumors.
Results and major updates from the DTRF Radiomics Working Group will be added to this page on an ongoing basis.
For questions related to this project, please contact email@example.com.